Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B

Arthritis Care & Research , 04/26/2012

Use of abatacept in patients with rheumatoid arthritis (RA) and chronic hepatitis B appears feasible if antiviral prophylaxis for hepatitis B is given concurrently. In these patients there were no non–hepatitis–related adverse effects. These data are encouraging and should lead to initiation of controlled trials of abatacept in hepatitis B.

Print Article Summary Cat 2 CME Report